Your browser is no longer supported. Please, upgrade your browser.
Settings
APRI Apricus Biosciences, Inc. daily Stock Chart
APRI [NASD]
Apricus Biosciences, Inc.
Index- P/E- EPS (ttm)-0.83 Insider Own4.20% Shs Outstand13.19M Perf Week-7.77%
Market Cap23.48M Forward P/E4.94 EPS next Y0.36 Insider Trans1.11% Shs Float11.76M Perf Month-3.26%
Income-6.70M PEG- EPS next Q-0.16 Inst Own35.60% Short Float10.76% Perf Quarter69.52%
Sales4.70M P/S5.00 EPS this Y70.20% Inst Trans44.68% Short Ratio3.33 Perf Half Y11.25%
Book/sh0.58 P/B3.07 EPS next Y144.40% ROA73.50% Target Price3.38 Perf Year-44.55%
Cash/sh0.59 P/C3.01 EPS next 5Y- ROE-262.30% 52W Range0.86 - 4.07 Perf YTD36.92%
Dividend- P/FCF- EPS past 5Y34.00% ROI- 52W High-56.27% Beta0.51
Dividend %- Quick Ratio- Sales past 5Y9.80% Gross Margin23.70% 52W Low106.98% ATR0.13
Employees15 Current Ratio4.70 Sales Q/Q- Oper. Margin- RSI (14)49.05 Volatility8.60% 6.94%
OptionableNo Debt/Eq0.00 EPS Q/Q71.10% Profit Margin- Rel Volume0.87 Prev Close1.85
ShortableYes LT Debt/Eq0.00 EarningsNov 07 AMC Payout0.00% Avg Volume379.66K Price1.78
Recom2.00 SMA20-2.13% SMA508.47% SMA2005.77% Volume331,998 Change-3.78%
Apr-26-17Initiated Rodman & Renshaw Buy $4
Nov-06-15Reiterated FBR Capital Outperform $22 → $19
Nov-06-15Downgrade ROTH Capital Buy → Neutral $1.50
Jul-23-12Initiated Ascendiant Capital Markets Strong Buy $6
Jun-14-12Initiated JMP Securities Mkt Outperform $6
Dec-14-10Initiated Dawson James Buy $5.50
Oct-10-17 07:59PM  Should You Be Concerned About Apricus Biosciences Incs (APRI) Risks? Simply Wall St.
07:02AM  Apricus Biosciences to Present at the 2017 BIO Investor Forum GlobeNewswire
Oct-03-17 09:00AM  SeeThruEquity Issues Company Update on Apricus Biosciences (NASDAQ:APRI) with Target Price of $4.30 ACCESSWIRE
Sep-11-17 07:00AM  Apricus Biosciences Announces $3.7 Million Private Placement Priced At-The-Market GlobeNewswire
Sep-06-17 08:31AM  Apricus, Topical Formulations Leading the Way, Q2 Review, and Outlook ACCESSWIRE
Sep-05-17 07:01AM  Apricus Biosciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference GlobeNewswire
Aug-31-17 07:00AM  Apricus Biosciences Announces FDA Acknowledgement of Vitaros Class 2 NDA Resubmission GlobeNewswire
Aug-29-17 07:00AM  Apricus Biosciences Files NDA Resubmission for Vitaros GlobeNewswire
Aug-23-17 06:01PM  Edited Transcript of APRI earnings conference call or presentation 2-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-11-17 04:56PM  ETFs with exposure to Apricus Biosciences, Inc. : August 11, 2017 Capital Cube
Aug-02-17 10:55PM  Apricus reports 2Q loss Associated Press -6.99%
04:02PM  Apricus Biosciences Provides Corporate Update and Second Quarter 2017 Financial Results GlobeNewswire
10:00AM  Investor Network: APRICUS BIOSCIENCES, INC. to Host Earnings Call ACCESSWIRE
Jul-26-17 07:01AM  Apricus Biosciences Announces Corporate Update and Second Quarter 2017 Financial Results Conference Call GlobeNewswire +12.50%
May-19-17 04:56AM  Edited Transcript of APRI earnings conference call or presentation 11-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-11-17 07:10PM  Edited Transcript of APRI earnings conference call or presentation 11-May-17 8:30pm GMT Thomson Reuters StreetEvents +7.63%
05:50PM  Apricus posts 1Q profit Associated Press
04:02PM  Apricus Biosciences Provides Corporate Update and First Quarter 2017 Financial Results GlobeNewswire
03:25PM  Investor Network: APRICUS BIOSCIENCES, INC. to Host Earnings Call Accesswire
May-04-17 07:01AM  Apricus Biosciences Announces the Initiation of Vitaros Drug-Device Human Factors Study GlobeNewswire
06:46AM  Apricus Biosciences Announces Corporate Update and First Quarter 2017 Financial Results Conference Call GlobeNewswire
May-02-17 04:06PM  Apricus Biosciences Regains Compliance with Nasdaq Continued Listing Requirements GlobeNewswire -10.62%
Apr-21-17 06:01AM  Apricus Biosciences Announces Pricing of $7.0 Million Public Offering GlobeNewswire -12.41%
Apr-19-17 02:09PM  ETFs with exposure to Apricus Biosciences, Inc. : April 19, 2017 Capital Cube
Apr-13-17 07:30AM  Apricus Biosciences and Protalix Biotherapeutics Seeing Opposite Sides of FDA Clinical Trials Accesswire -11.82%
Apr-07-17 03:49PM  ETFs with exposure to Apricus Biosciences, Inc. : April 7, 2017 Capital Cube -6.08%
Mar-27-17 03:48PM  ETFs with exposure to Apricus Biosciences, Inc. : March 27, 2017 Capital Cube
03:48PM  ETFs with exposure to Apricus Biosciences, Inc. : March 27, 2017
Mar-20-17 09:03AM  Apricus Biosciences, Inc. :APRI-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Capital Cube
09:03AM  Apricus Biosciences, Inc. :APRI-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
Mar-17-17 01:04PM  APRICUS BIOSCIENCES, INC. Financials
Mar-13-17 05:22PM  Apricus reports 4Q loss Associated Press +7.20%
04:30PM  Apricus Biosciences Inc Earnings Call scheduled for 4:30 pm ET today
04:20PM  Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
04:19PM  APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:13PM  Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
07:07AM  Q4 2016 Apricus Biosciences Inc Earnings Release - 4:01 pm ET
Mar-09-17 01:32PM  Apricus Biosciences Sells ED Therapy Rights Investopedia
01:32PM  Apricus Biosciences Sells ED Therapy Rights at Investopedia
07:02AM  Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2016 Financial Results Conference Call GlobeNewswire
07:00AM  Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2016 Financial Results Conference Call GlobeNewswire
Mar-08-17 04:04PM  APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material D
04:02PM  Apricus Biosciences Announces Sale of Ex-U.S. Vitaros Assets and Rights to Ferring Pharmaceuticals GlobeNewswire
04:01PM  Apricus Biosciences Announces Sale of Ex-U.S. Vitaros Assets and Rights to Ferring Pharmaceuticals GlobeNewswire
Feb-09-17 06:06AM  APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events
06:02AM  Apricus Biosciences Receives Positive Nasdaq Listing Determination GlobeNewswire
06:00AM  Apricus Biosciences Receives Positive Nasdaq Listing Determination GlobeNewswire
Feb-08-17 07:01AM  Apricus Biosciences to Present at the 19th Annual BIO CEO & Investor Conference GlobeNewswire
07:00AM  Apricus Biosciences to Present at the 19th Annual BIO CEO & Investor Conference GlobeNewswire
Jan-19-17 12:20PM  Thursdays Top Biopharma Movers 24/7 Wall St. -16.43%
09:04AM  Apricus (APRI) Stock Gains on Vitaros' Approval in Mexico
Jan-18-17 02:10PM  How Erectile Dysfunction in Mexico Just Made One Micro-Cap Stock More Than Double +89.40%
11:05AM  Wednesdays Top Biopharma Winners
07:01AM  Apricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in Mexico GlobeNewswire
07:00AM  Apricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in Mexico GlobeNewswire
Jan-13-17 09:30AM  Latest Reports on Biocept and Apricus Biosciences as President Trump's Comments Put Pressure on Drug Manufacturers Accesswire
Jan-03-17 07:01AM  Apricus Biosciences Promotes Mary Naggs to Vice President, General Counsel GlobeNewswire +5.38%
07:00AM  Apricus Biosciences Promotes Mary Naggs to Vice President, General Counsel GlobeNewswire
Dec-28-16 09:55AM  Apricus Launches Vitaros in Lebanon for Erectile Dysfunction
Dec-27-16 07:01AM  Apricus Biosciences Announces the Launch of Vitaros® for the Treatment of Erectile Dysfunction in Lebanon by Elis Pharmaceuticals GlobeNewswire -7.58%
07:00AM  Apricus Biosciences Announces the Launch of Vitaros® for the Treatment of Erectile Dysfunction in Lebanon by Elis Pharmaceuticals GlobeNewswire
Dec-23-16 04:12PM  APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers +10.92%
Dec-13-16 12:25PM  ETFs with exposure to Apricus Biosciences, Inc. : December 13, 2016 -20.11%
Dec-12-16 09:30AM  Zacks.com featured highlights: Baxter International, MAM Software Group, Advanced Energy Industries, Apricus Biosciences and Copart +57.02%
Dec-09-16 09:44AM  5 Efficient Stocks to Buy for Superlative Returns -5.00%
Dec-01-16 07:01AM  Apricus Biosciences Receives Nasdaq Compliance Notice GlobeNewswire -11.27%
07:00AM  Apricus Biosciences Receives Nasdaq Compliance Notice GlobeNewswire
06:03AM  APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or S
Nov-29-16 07:01AM  Apricus Biosciences to Present at the 9th Annual LD Micro Main Event GlobeNewswire
07:00AM  Apricus Biosciences to Present at the 9th Annual LD Micro Main Event GlobeNewswire
Nov-22-16 06:02AM  APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Nov-21-16 08:39AM  Apricus Biosciences Aims to Resubmit Vitaros NDA in 2017
Nov-18-16 07:11AM  APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events -15.35%
07:02AM  Apricus Biosciences Provides Update on Vitaros NDA Following Receipt of FDA Feedback GlobeNewswire
07:00AM  Apricus Biosciences Provides Update on Vitaros NDA Following Receipt of FDA Feedback GlobeNewswire
Nov-16-16 12:39PM  ETFs with exposure to Apricus Biosciences, Inc. : November 16, 2016
Nov-14-16 12:09PM  Apricus Biosciences, Inc. :APRI-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016
Nov-09-16 12:47PM  Edited Transcript of APRI earnings conference call or presentation 8-Nov-16 9:30pm GMT +16.82%
Nov-08-16 04:34PM  Apricus reports 3Q loss
04:30PM  Apricus Biosciences Inc Earnings Call scheduled for 4:30 pm ET today
04:15PM  APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:03PM  Apricus Biosciences Provides Corporate Update and Third Quarter Financial Results GlobeNewswire
04:01PM  Apricus Biosciences Provides Corporate Update and Third Quarter Financial Results GlobeNewswire
07:07AM  Q3 2016 Apricus Biosciences Inc Earnings Release - 4:01 pm ET
Nov-02-16 07:02AM  Apricus Biosciences Announces Corporate Update and Third Quarter 2016 Financial Results Conference Call GlobeNewswire -12.83%
07:00AM  Apricus Biosciences Announces Corporate Update and Third Quarter 2016 Financial Results Conference Call GlobeNewswire
Nov-01-16 02:47PM  Drug Makers Stocks Under Scanner -- Pernix Therapeutics, Novo Nordisk, Synergy Pharma, and Apricus Biosciences PR Newswire -6.97%
Oct-26-16 07:00AM  Apricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in Greece GlobeNewswire
Oct-25-16 04:12PM  APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Material Modification to Rights of Security Holders, Amendments to Arti
12:07PM  Here Are Two Biotechs That Are Down But Could Recover Near Term at Insider Monkey
Oct-24-16 07:03AM  Splits Calendar: Apricus Biosciences splits before market open today (1:10 ratio) -10.99%
Oct-20-16 04:31PM  Apricus Biosciences Announces 1-for-10 Reverse Stock Split GlobeNewswire
04:30PM  Apricus Biosciences Announces 1-for-10 Reverse Stock Split GlobeNewswire
Oct-13-16 09:26AM  ETFs with exposure to Apricus Biosciences, Inc. : October 13, 2016
Oct-12-16 07:02AM  Apricus Biosciences to Present at the 2016 BIO Investor Forum GlobeNewswire -5.71%
07:00AM  Apricus Biosciences to Present at the 2016 BIO Investor Forum GlobeNewswire
Sep-28-16 07:02PM  Apricus Biosciences Closes $3.7 Million Registered Direct Offering GlobeNewswire
07:00PM  Apricus Biosciences Closes $3.7 Million Registered Direct Offering GlobeNewswire
05:27PM  APRICUS BIOSCIENCES, INC. Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Termination of a Material
08:36AM  APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material D
Apricus Biosciences, Inc., a biopharmaceutical company, focuses on the development and commercialization of product candidates in the areas of urology and rheumatology. Its lead product is Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction. The company also engages in developing RayVa, which is in Phase 2 development for the treatment of Raynaud's Phenomenon associated with scleroderma; and Fispemifene, a tissue-specific selective estrogen receptor modulator for the treatment of secondary hypogonadism, chronic prostatitis, and lower urinary tract symptoms in men. It operates in Europe, Canada, Latin America, and the Asia Pacific. The company was formerly known as NexMed, Inc. and changed its name to Apricus Biosciences, Inc. in September 2010. Apricus Biosciences, Inc. was founded in 1987 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DENNER ALEXANDER J10% OwnerAug 31Buy1.636,1049,9501,447,906Sep 01 04:26 PM